Danam Health Files S-1/A for IPO

TL;DR

Danam Health IPO update filed 9/27. Looks like they're serious about going public.

AI Summary

Danam Health, Inc. filed an S-1/A amendment on September 27, 2024, for its initial public offering. The company, incorporated in Delaware, is based in Tampa, Florida, and operates in the wholesale drugs, proprietaries, and druggists' sundries sector. The filing includes details on its principal executive offices and agent for service, Timothy Canning.

Why It Matters

This S-1/A filing indicates Danam Health is moving forward with its public offering, which could provide capital for expansion and increase market visibility.

Risk Assessment

Risk Level: medium — As an S-1/A filing, it represents a company seeking to go public, which inherently carries market and execution risks.

Key Numbers

• 333-280945 — SEC File Number (Identifies the specific registration statement)

Key Players & Entities

• Danam Health, Inc. (company) — Registrant
• September 27, 2024 (date) — Filing Date
• 3000 Bayport Drive Suite 950 Tampa, FL 33607 (location) — Principal Executive Offices
• Timothy Canning (person) — Agent for Service
• 333-280945 (registration_number) — SEC File Number

FAQ

Key Financial Figures

• $0.001 — o; refer to the common stock, par value $0.001 per share, of Danam Health, Inc. Certa

Filing Documents

• forms-1a.htm (S-1/A) — 2540KB
• ex1-1.htm (EX-1.1) — 338KB
• ex2-2.htm (EX-2.2) — 1126KB
• ex10-11.htm (EX-10.11) — 52KB
• ex23-1.htm (EX-23.1) — 3KB
• formdrs_001.jpg (GRAPHIC) — 19KB
• formdrs_002.jpg (GRAPHIC) — 75KB
• formdrs_003.jpg (GRAPHIC) — 148KB
• formdrs_015.jpg (GRAPHIC) — 248KB
• formdrs_016.jpg (GRAPHIC) — 216KB
• 0001493152-24-038464.txt ( ) — 5034KB

Underwriting

Underwriting discount (1) $ $ Proceeds, before expenses, to us (2) $ $ (1) We have agreed to pay the representative a discount equal to 7% of the gross proceeds of the Offering. For a description of the other compensation to be received by the representative, see “ Underwriting ” beginning on page 99. (2) Excludes fees and expenses payable to the underwriters and other expenses of this Offering. The underwriters are offering the units on a firm commitment basis and expects to deliver the Common Stock to purchasers on or about [], 2024. Craft Capital Management LLC EF Hutton LLC The date of this prospectus is [], 2024 TABLE OF CONTENTS Page ABOUT THIS PROSPECTUS 1 MARKET AND INDUSTRY DATA 1 FREQUENTLY USED TERMS 2 PROSPECTUS SUMMARY 5 THE OFFERING 9

RISK FACTORS

RISK FACTORS 10 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS 41

USE OF PROCEEDS

USE OF PROCEEDS 42 DIVIDEND POLICY 43 CAPITALIZATION 44

SELECTED FINANCIAL DATA

SELECTED FINANCIAL DATA 46 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION 47 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF DANAM 51 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF WELLGISTICS 56

BUSINESS

BUSINESS 63 MANAGEMENT 81

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 86 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 88 PRINCIPAL STOCKHOLDERS 90

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 91 SHARES ELIGIBLE FOR FUTURE SALE 94 MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES 95

UNDERWRITING

UNDERWRITING 99 LEGAL MATTERS 103 EXPERTS 103 WHERE YOU CAN FIND MORE INFORMATION 103 INDEX TO FINANCIAL STATEMENTS F-1 DEALER PROSPECTIVE DELIVERY OBLIGATION Until [ ], all dealers that effect transactions in these securities, whether or not participating in this Offering, may be required to deliver a prospectus. This is in addition to the dealers’ obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. i ABOUT THIS PROSPECTUS You should rely only on the information contained in this prospectus or in any related free-writing prospectus. We and the underwriters have not authorized anyone to provide you with information or to make any representations other than contained in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for and can provide no assurance as to the reliability of any other information that others may give you. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information appearing in this prospectus, any post-effective amendment, and any applicable prospectus supplement to this prospectus is accurate only as of the date on its respective cover. Our business, financial condition, results of operations and prospects may have changed since those dates. We are not making an offer to sell our Common Stock in any jurisdiction where the offer or sale thereof is not permitted. You should not assume that the information appearing in this prospectus any post-effective amendment, and any applicable prospectus supplement to this prospectus is accurate as of any date other than their respective dates. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read carefully the entirety of t

View Full Filing

View this S-1/A filing on SEC EDGAR